熱門資訊> 正文
眼部疾病药物第二阶段失败后，KALA比奥股价暴跌92%
2025-09-29 20:56
- Shares of KALA Bio (BIO) have plummeted ~92% in premarket trading Monday after reporting that a phase 2 trial of its persistent corneal epithelial defect (PCED) candidate KPI-012 missed its key goal.
- Besides missing the primary endpoint of complete healing of PCED as measured by corneal fluorescein staining, the CHASE trial also missed on secondary efficacy endpoints.
- As a result, KALA will end development of KPI-012 -- which was its lead product -- along with its mesenchymal stem cell secretome (MSC-S) platform.
- Also, the company will evaluate strategic options and preserve cash, including cutting staff.
More on KALA BIO
- Seeking Alpha’s Quant Rating on KALA BIO
- Historical earnings data for KALA BIO
- Financial information for KALA BIO
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
